Scalper1 News
The bull case for Amgen’s (AMGN) new cholesterol drug Repatha continued to be built Tuesday, as Nomura raised long-term estimates on the drug’s sales while UBS defended its optimistic thesis for both Repatha and rival drug Praluent, from Sanofi (SNY) and Regeneron (REGN). After surveying 30 cardiologists who were enthusiastic about the new anti-PCSK9 drug class, Nomura analyst Ian Somaiya hiked his 2018 estimate on Repatha to $2.1 billion from Scalper1 News
Scalper1 News